Last Price | 1.44 | Max Price | 10.99 |
Min Price | 1.20 | 1 Year return | -63.82 |
Sector | Health Care | Subsector | Pharmaceuticals |
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 0 | 615,634 | 0.00 % |
2020 | 2 | 638,070 | 0.00 % |
2021 | 15 | 727,968 | 0.00 % |
2022 | 25 | 787,273 | 0.00 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
No Records Found
No Records Found
The stock lost over the past 12 months at around 86 percent. Over the past 5 years Marinus Pharmaceuticals Inc' stock lost at around 0 percent in value. Marinus Pharmaceuticals Inc's revenues between 2011 and 2015 were very fluctuating and moved between 0,1 million dollars and 0 million dollars.
The core activities of Marinus Pharmaceuticals Inc are in the pharmaceutical sector. The period from 2006 till the end of 2016 the international sector gained around 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-2016) there is a minus of 75 percent.
Over the past 5 years the American company paid out dividends.
At the end of 2015 the pharmaceutical company's balance sheet was worth 59,66 million dollars. Last year the total debt of the company was 12,74 million dollars. This equals around 21,35 percent of the total balance sheet. At the end of 2015 the pharmaceutical company's stock was traded with a price/earnings-ratio -6. So the stock' value was -6 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a value stock.
At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the pharmaceutical company equaled around 105,93 million dollars. At the end of 2015 the American company had around 14,92 million stocks listed on the stock exchange(s).
All the company's financial reports are available here. More information about Marinus Pharmaceuticals Inc can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
0
|
0
|
0
|
0
|
0
|
2
|
Costs |
25
|
29
|
19
|
37
|
54
|
78
|
Profit |
-25
|
-29
|
-19
|
-37
|
-54
|
-76
|
Margin of profit |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
-4439.53
|
ROI |
-52.96
|
-133.33
|
-32.58
|
-53.75
|
-61.66
|
-55.66
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
47
|
21
|
58
|
68
|
88
|
137
|
Debt |
13
|
10
|
3
|
7
|
11
|
13
|
Total assets |
60
|
31
|
61
|
75
|
99
|
150
|
Solvency |
78.66
|
68.30
|
95.62
|
90.83
|
88.80
|
91.19
|
Cash |
56
|
30
|
53
|
73
|
92
|
140
|
Cashflow |
-20
|
-25
|
-19
|
-28
|
-49
|
-61
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
-1.58
|
-2.48
|
-7.08
|
-4.03
|
-4.39
|
-4.59
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
30.56
|
4.04
|
32.64
|
11.48
|
8.64
|
Eps |
-5.88
|
-3.21
|
-3.59
|
-3.97
|
-2.80
|
Price/earnings-ratio |
-5.20
|
-1.26
|
-9.09
|
-2.89
|
-0.51
|
Dividend |
0.0
|
0.0
|
0.0
|
0.0
|
|
Dividend % |
0.00 %
|
0.00 %
|
0.00 %
|
0.00 %
|
|
Payout % |
0.0
|
0.0
|
0.0
|
0.0
|
|
Book value |
4.36
|
5.73
|
5.20
|
4.06
|
3.75
|
Market to book |
0.14
|
1.42
|
0.16
|
0.35
|
2.60
|
Cashflow per stock |
-5.03
|
-1.86
|
-2.12
|
-2.25
|
-1.67
|
Stocks |
5
|
10
|
13
|
22
|
37
|
Market Cap |
150.55
|
40.93
|
428.56
|
248.17
|
52.67
|
Date
|
Price
|
---|---|
18 Apr 2024
|
1.44
|
17 Apr 2024
|
1.20
|
09 Apr 2024
|
8.20
|
05 Apr 2024
|
8.68
|
03 Apr 2024
|
8.87
|
30 Mar 2024
|
9.04
|
22 Mar 2024
|
9.01
|
18 Mar 2024
|
9.39
|
15 Mar 2024
|
8.95
|
12 Mar 2024
|
8.48
|
11 Mar 2024
|
8.85
|
09 Mar 2024
|
8.85
|
07 Mar 2024
|
9.03
|
01 Mar 2024
|
9.50
|
29 Feb 2024
|
9.86
|
27 Feb 2024
|
9.99
|
22 Feb 2024
|
9.75
|
21 Feb 2024
|
9.54
|
20 Feb 2024
|
9.96
|
15 Feb 2024
|
10.01
|
14 Feb 2024
|
9.90
|
13 Feb 2024
|
10.21
|
09 Feb 2024
|
9.99
|
08 Feb 2024
|
9.91
|
07 Feb 2024
|
10.00
|
06 Feb 2024
|
9.94
|
05 Feb 2024
|
9.98
|
01 Feb 2024
|
9.74
|
31 Jan 2024
|
9.99
|
30 Jan 2024
|
10.16
|